Benyamin Toker

Molecular Devices LLC engages in the provision of bioanalytical solutions for protein and cell biology in life science research, pharmaceutical, and bio-therapeutic development. Its product portfolio includes platforms for screening, genomic and cellular analysis, colony selection, and microplate detection. The company was founded by Harden M. McConnell in July, 1983 and is headquartered in San Jose, CA.

FlowMedica, Inc. develops intravascular systems and medical devices. The company's products include Benephit CV, PVSolo, PVMini, and XT Infusion systems. It also develops novel, proprietary, and minimally invasive intravascular systems for implementing Targeted Renal Therapy. The company was founded in 2002 and is headquartered in Fremont, CA.

Ablative Solutions, Inc. develops and markets endovascular catheters for the treatment of hypertension. It offers solutions for heart failure, kidney disease, metabolic syndrome, and sleep apnea. The company was founded by Tim A. Fischell and David R. Fischell in 2011 and is headquartered in San Jose, CA.

Biometric Imaging, Inc. manufactures cellular analysis instruments. It offers services to clinics, hospitals, blood banks, and cancer management centers for disease management and therapy monitoring. The company was founded by Bala S. Manian in 1992 and is headquartered in Mountain View, CA.

Vascular Therapeutics, Inc. develops glycol therapeutics for cardiovascular diseases. The firm also discovers and develops therapeutic agents to prevent & treat life-threatening blood clotting disorders. It serves cardiovascular diseases such as acute myocardial infarction, stroke, pulmonary embolism and deep vein thrombosis. The company was founded in July, 1994 and is headquartered in Mountain View, CA.

Neurofluidics, Inc. develops neurological therapies. It also develops targeted and logical treatment approaches for patients suffering from neurological disorders. The company was founded in 2008 and is headquartered in Menlo Park, CA.

Amaros, Inc. develops artificial intelligence for clinical development and post-market monitoring of therapeutics. The CEO of the American company is Vartan E. Ghazarossian.

Part of Amring Pharmaceuticals, Inc., Visant Medical, Inc. is a clinical-stage medical device company based in Menlo Park, CA. Symatese SAS, a French company based in Lyon, was instrumental in the development of Lacrifill, significantly enhancing the product's design and performance, by leveraging its expertise in tissue regeneration, reconstruction, and related delivery systems. The company received FDA 510 (k) clearance in 2022 for Lacrifill® cross-linked hyaluronic acid-based canalicular occlusive device, which is intended to block tear drainage by occlusion of the canalicular system. The device is indicated for use, for up to 6 months, in patients experiencing dry eye symptoms. The company specializes in injectable crosslinked HA gels for many markets, including aesthetic, rheumatology, and ophthalmology. Symatese designs the most advanced medical device solutions thanks to their technology portfolio in hyaluronic acid, collagen, thermoplastics, and silicone. The company was founded by Cary J. Reich and Vartan E. Ghazarossian. Vartan E. Ghazarossian has been the CEO since incorporation. Visant Medical was acquired by Amring Pharmaceuticals, Inc. on December 18, 2023.